| The effects of lowering uric acid levels using allopurinol on markers of metabolic syndrome in end-stage renal disease patients: a pilot study. | |
| | |
MedLine Citation:
|
PMID: 19819789 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Allopurinol was administered to end-stage renal disease (ESRD) patients with elevated uric acid levels presenting with symptoms of gout and also had risk factors of metabolic syndrome. The primary aim of this pilot study was to examine the effects of lowering uric acid levels using allopurinol on lipoprotein markers of metabolic syndrome in patients. METHODS: The study was conducted using a prospective open-label protocol. End-stage renal disease patients (n=12) (mean age: 45.8+/- 13.6 years) undergoing chronic hemodialysis were recruited through their treating physician to participate in this study. All patients had ESRD and were prescribed allopurinol (300 mg/bid) for gout over a 3-month period. Pre-allopurinol and post-allopurinol data was obtained on low-density lipoprotein (LDL) cholesterol, LDL particle number, LDL particle size, high-density lipoprotein (HDL) cholesterol, large HDL particle number, total cholesterol, triglycerides, large very-low density lipoprotein (VLDL) particle number, and uric acid. Changes in lipid values were measured using a one-sample exact Wilcoxon rank sum test. RESULTS: Significant changes occurred in the primary outcome measures of serum uric acid levels (-3.53 mg/dL, p=0.01), LDL cholesterol (-14.00 mg/dL, p=0.04), and triglycerides (32.67 mg/dL, p=0.01). Trends were observed in lipid markers that warrant further investigation. CONCLUSION: Novel findings of our study suggest that lowering uric acid in ESRD patients may help to reduce the risk of cardiovascular disease in this population. It should be noted than an increase in triglycerides may mitigate the reduction in risk. |
| | |
Authors:
|
Brian Shelmadine; Rodney G Bowden; Ronald L Wilson; Daniel Beavers; Jessica Hartman |
Related Documents
:
|
7091159 - Cholesterol reduction by a high-glucose diet in a patient with homozygous familial hype... 7598139 - Effects of continuous combined hormone-replacement therapy on lipid levels in hyperchol... 21270369 - Adherence index based on the aha 2006 diet and lifestyle recommendations is associated ... 2975629 - Metabolic effects of combined cyproterone acetate and percutaneous 17 beta oestradiol a... 17193859 - Food intake and high density lipoprotein cholesterol levels changes during ramadan fast... 11805009 - Inaccuracy of lipid measurements with the portable cholestech l.d.x analyzer in patient... 12847129 - Geographic variation in energy storage and physiological responses to freezing in the g... 8988909 - Consumption of cow milk and egg by lactating women and the presence of beta-lactoglobul... 22191449 - The relationship between gut microbiota and weight gain in humans. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology Volume: 9 ISSN: 1308-0032 ISO Abbreviation: Anadolu Kardiyol Derg Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-12 Completed Date: 2010-02-17 Revised Date: 2010-06-15 |
Medline Journal Info:
|
Nlm Unique ID: 101095069 Medline TA: Anadolu Kardiyol Derg Country: Turkey |
Other Details:
|
Languages: eng Pagination: 385-9 Citation Subset: IM |
Affiliation:
|
Baylor University, School of Education, Waco, Texas, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Allopurinol / therapeutic use* Cholesterol, HDL / blood, drug effects Cholesterol, LDL / blood, drug effects Diabetes Mellitus, Type 2 / complications Female Gout Suppressants / therapeutic use Humans Kidney Failure, Chronic / blood, physiopathology*, therapy Male Metabolic Syndrome X / blood, epidemiology, prevention & control Middle Aged Pilot Projects Renal Dialysis Triglycerides / blood Uric Acid / blood* |
| Chemical | |
Reg. No./Substance:
|
0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Gout Suppressants; 0/Triglycerides; 315-30-0/Allopurinol; 69-93-2/Uric Acid |
| Comments/Corrections | |
Comment In:
|
Anadolu Kardiyol Derg. 2010 Jun;10(3):294-5; author reply 295-6
[PMID:
20538573
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The cardiac effects of a mobile phone positioned closest to the heart.
Next Document: Efficacy of gabapentin versus diclofenac in the treatment of chest pain and paresthesia in patients ...